Blog
RSS FeedPosted by Michael Wonder on 20 Apr 2021
NICE draft guidance provides Cancer Drugs Fund first in Europe access to new treatment option for advanced breast cancer
20 April 2021 - NICE has today published draft guidance recommending trastuzumab deruxtecan for use in the Cancer Drugs Fund for ...
Posted by Michael Wonder on 15 Apr 2021
NICE publishes draft guidance on new use for fenfluramine hydrochloride
15 April 2021 - The Department of Health and Social Care has asked NICE to produce guidance on using fenfluramine hydrochloride ...
Posted by Michael Wonder on 15 Apr 2021
Alexion's pricey Ultomiris wins backing from England's cost watchdogs thanks to confidential discount
15 April 2021 - Alexion has added a nice piece to Ultomiris’ growth potential ahead of its planned merger with ...
Posted by Michael Wonder on 08 Apr 2021
NICE publishes guidance on nivolumab - ipilumumab combo
8 April 2021 - The Department of Health and Social Care has asked NICE to produce guidance on using nivolumab with ...
Posted by Michael Wonder on 06 Apr 2021
NICE backs restricted use of Ondexxya
6 April 2021 - NHS cost regulators have backed funding for Alexion's Ondexxya (andexanet alfa) to reverse anti-coagulation of the ...
Posted by Michael Wonder on 31 Mar 2021
NICE recommends Sobi’s Kineret for first-line use in Still’s disease
31 March 2021 - NICE has approved Kineret (anakinra) to treat systemic juvenile idiopathic arthritis in people aged eight months ...
Posted by Michael Wonder on 24 Mar 2021
NICE publishes draft guidance for secukinumab (Cosentyx)
24 March 2021 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...
Posted by Michael Wonder on 24 Mar 2021
NICE publishes draft guidance for ixekizumab (Taltz)
24 March 2021 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...
Posted by Michael Wonder on 19 Mar 2021
Ovarian cancer patients to have NICE approved drug combination option on Cancer Drugs Fund
19 March 2021 - A potentially life-extending drug combination for some people with advanced, high-grade epithelial ovarian, fallopian tube or primary ...
Posted by Michael Wonder on 19 Mar 2021
NICE rejects Keytruda for advanced bladder cancer in final guidance
18 March 2021 - The UK’s NICE has issued a second final appraisal document rejecting MSD’s Keytruda for the treatment ...
Posted by Michael Wonder on 18 Mar 2021
UK approval for Daiichi Sankyo’s cholesterol lowering treatments
18 March 2021 - Daiichi Sankyo’s cholesterol-lowering drugs Nilemdo and Nustendi have been approved by the UK National Institute for ...
Posted by Michael Wonder on 10 Mar 2021
NICE publishes updated guidance on the use of pembrolizumab (Keytruda) for patients with untreated, metastatic, non-squamous non-small-cell lung cancer
10 March 2021 - Pembrolizumab was listed in the Cancer Drugs Fund for this indication. ...
Posted by Michael Wonder on 10 Mar 2021
NICE finally publishes final guidance for Aimovig
10 March 2021 - Erenumab has been recommended by NICE for certain patients with migraine. ...
Posted by Michael Wonder on 08 Mar 2021
NICE approves life changing gene therapy for treating spinal muscular atrophy
8 March 2021 - A new and potentially curative one-off gene therapy for babies with the rare genetic disorder spinal muscular ...
Posted by Michael Wonder on 04 Mar 2021
NICE rejects rare blood cancer treatment Poteligeo in final appraisal
4 March 2021 - The UK’s NICE has not recommended Kyowa Kirin’s Poteligeo for the treatment of adults living with ...